CN112424222A - 使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗 - Google Patents

使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗 Download PDF

Info

Publication number
CN112424222A
CN112424222A CN201980026429.9A CN201980026429A CN112424222A CN 112424222 A CN112424222 A CN 112424222A CN 201980026429 A CN201980026429 A CN 201980026429A CN 112424222 A CN112424222 A CN 112424222A
Authority
CN
China
Prior art keywords
cancer
antibody
modulator
subject
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980026429.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·雷德卡
M·雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guanke Meibo Co ltd
Original Assignee
Guanke Meibo Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guanke Meibo Co ltd filed Critical Guanke Meibo Co ltd
Publication of CN112424222A publication Critical patent/CN112424222A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980026429.9A 2018-02-17 2019-02-17 使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗 Pending CN112424222A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631771P 2018-02-17 2018-02-17
US62/631,771 2018-02-17
US201862757729P 2018-11-08 2018-11-08
US62/757,729 2018-11-08
PCT/US2019/018377 WO2019161320A1 (en) 2018-02-17 2019-02-17 Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint

Publications (1)

Publication Number Publication Date
CN112424222A true CN112424222A (zh) 2021-02-26

Family

ID=67620025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980026429.9A Pending CN112424222A (zh) 2018-02-17 2019-02-17 使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗

Country Status (6)

Country Link
US (1) US20200405719A1 (https=)
EP (1) EP3752528A4 (https=)
JP (2) JP2021515032A (https=)
CN (1) CN112424222A (https=)
CA (1) CA3091373A1 (https=)
WO (1) WO2019161320A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3091373A1 (en) * 2018-02-17 2019-08-22 Apollomics Inc. Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
JP2023523295A (ja) * 2020-04-26 2023-06-02 アポロミクス インコーポレイテッド Ｃ－ｍｅｔ阻害剤のための新規医薬製剤
EP4159238A4 (en) * 2020-06-02 2024-08-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY
CN113105436B (zh) * 2021-04-20 2022-07-01 西格莱(苏州)生物医药有限公司 吡唑类化合物的制备方法及其中间体
WO2023172629A2 (en) * 2022-03-08 2023-09-14 Brown University Anticancer maleimide derivatives for use with immune checkpoint blockade
WO2025129332A1 (en) * 2023-12-21 2025-06-26 11949098 Canada Inc. (Nuredco) C/O Jean I. Tchervenkov Method of prognosis and monitoring of cancer patient and of determining immunological status of a subject

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120237522A1 (en) * 2008-10-02 2012-09-20 Seoul National University Industry Foundation Anticancer agent comprising anti-pd-1 antibody or anti-pd-l1 antibody
US20150218171A1 (en) * 2012-09-03 2015-08-06 Crown Bioscience Inc. (Taiwan) Highly selective c-met inhibitors as anticancer agents
WO2016014688A2 (en) * 2014-07-22 2016-01-28 Junzhuan Qiu Anti-pd-1 antibodies
WO2016022630A1 (en) * 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
WO2017106810A2 (en) * 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
CN107106687A (zh) * 2014-10-03 2017-08-29 诺华股份有限公司 组合治疗
JP2017537112A (ja) * 2014-12-04 2017-12-14 ヤンセン ファーマシューティカ エンヴェー キナーゼモジュレーターとしての重水素化トリアゾロピリダジン
CN107667119A (zh) * 2015-05-12 2018-02-06 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
CN115697407A (zh) * 2020-06-02 2023-02-03 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3122900A1 (en) * 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CA3000386A1 (en) * 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
CA3091373A1 (en) * 2018-02-17 2019-08-22 Apollomics Inc. Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120237522A1 (en) * 2008-10-02 2012-09-20 Seoul National University Industry Foundation Anticancer agent comprising anti-pd-1 antibody or anti-pd-l1 antibody
US20150218171A1 (en) * 2012-09-03 2015-08-06 Crown Bioscience Inc. (Taiwan) Highly selective c-met inhibitors as anticancer agents
WO2016014688A2 (en) * 2014-07-22 2016-01-28 Junzhuan Qiu Anti-pd-1 antibodies
WO2016022630A1 (en) * 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
CN107106687A (zh) * 2014-10-03 2017-08-29 诺华股份有限公司 组合治疗
JP2017537112A (ja) * 2014-12-04 2017-12-14 ヤンセン ファーマシューティカ エンヴェー キナーゼモジュレーターとしての重水素化トリアゾロピリダジン
CN107667119A (zh) * 2015-05-12 2018-02-06 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
WO2017106810A2 (en) * 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
CN115697407A (zh) * 2020-06-02 2023-02-03 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GLODDE 等: "Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy", IMMUNITY, vol. 47, 17 October 2017 (2017-10-17), pages 794 *
KIRIU 等: "The time-series behavior of neutrophil-tolymphocyte ratio is useful as a predictive marker in non-small cell lung cancer", PLOS ONE, vol. 13, no. 2, 15 February 2018 (2018-02-15), pages 0193018 *
匡汪浩: "中药联合PD-1抑制剂、阿帕替尼及替吉奥治疗HER-2阴性晚期胃癌的真实世界研究", 中国优秀硕士学位论文全文数据库医药卫生科技辑, no. 01, 15 January 2022 (2022-01-15), pages 072 - 861 *

Also Published As

Publication number Publication date
JP2021515032A (ja) 2021-06-17
US20200405719A1 (en) 2020-12-31
EP3752528A1 (en) 2020-12-23
WO2019161320A1 (en) 2019-08-22
CA3091373A1 (en) 2019-08-22
EP3752528A4 (en) 2021-11-03
JP2024009886A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
Sahin et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18. 2-positive gastric and gastro-oesophageal adenocarcinoma
CN112424222A (zh) 使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗
Lameire Nephrotoxicity of recent anti-cancer agents
US11891450B2 (en) Anti-CD47 agent-based treatment of CD20-positive cancer
Rossi et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
CN110536905B (zh) 用于治疗肺癌的抗pd-1抗体
Rini et al. Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
JP7482180B2 (ja) 癌のための併用療法
US20180179282A1 (en) Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
JP2022082565A (ja) がんを処置するための方法
WO2016140717A1 (en) Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2018234879A1 (en) USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
Dickinson et al. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
CN109153722A (zh) 用于治疗癌症的方法
US20220249621A1 (en) TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS
US20220160718A1 (en) Compositions and methods of treating cancer
CN114502241A (zh) 抗半乳凝素-9抗体和化疗剂的联合癌症疗法
Quan et al. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer
Kuboki et al. PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study
Raucci et al. Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
US20220025036A1 (en) Use of il-1beta binding antibodies
JP7504106B2 (ja) がんの処置のための組合せ物
CN116134155A (zh) 通过施用pd-1抑制剂治疗癌症的方法
Erciyestepe et al. Distribution of side effects of anti-EGFR treatments in patients with metastatic colorectal cancer and evaluation of their relationship with survival
HK40096805A (zh) 用於组合疗法的患者的选择

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210226